

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
31 March 2022 (31.03.2022)



(10) International Publication Number
WO 2022/063892 A1

(51) International Patent Classification:

A61K 47/64 (2017.01) *A61K 39/23* (2006.01)
A61K 47/68 (2017.01) *A61K 39/235* (2006.01)
A61P 37/06 (2006.01) *A61K 39/385* (2006.01)
C07K 17/06 (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR, OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

(21) International Application Number:

PCT/EP2021/076193

(22) International Filing Date:

23 September 2021 (23.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20197898.8 23 September 2020 (23.09.2020) EP

(71) Applicant: **ABLEVIA BIOTECH GMBH** [AT/AT];
Maria-Jacobi-Gasse 1, 1030 Wien (AT).

(72) Inventors: **SMRZKA, Oskar**, c/o Ablevia biotech GmbH,
Maria-Jacobi-Gasse 1, 1030 Wien (AT). **WANKO, Betti-
na**, c/o Ablevia biotech GmbH, Maria-Jacobi-Gasse 1, 1030
Wien (AT).

(74) Agent: **SONN PATENTANWÄLTE OG**; Riemergasse
14, 1010 Wien (AT).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: COMPOUND FOR INCREASING EFFICACY OF VIRAL VECTORS

(57) Abstract: The present invention provides a compound for the sequestration of undesirable neutralizing antibodies against viral vectors (as used in vaccines and in gene therapy) in a patient. The compound comprises an inert biopolymer scaffold and at least a first peptide n-mer of the general formula P (— S — P)_(n-1) and a second peptide n-mer of the general formula P (— S — P)_(n-1); wherein, independently for each occurrence, P is a peptide with a sequence length of 2-13 amino acids and S is a non-peptide spacer, wherein, independently for each of the peptide n-mers, n is an integer of at least 1, wherein each of the peptide n-mers is bound to the biopolymer scaffold. Independently for each occurrence, P has an amino-acid sequence comprising a sequence fragment with a length of at least six amino acids of a capsid protein sequence of a viral vector. Also provided are pharmaceutical compositions comprising the compound, as well as a method of sequestering one or more antibodies present in an individual and a method of inhibiting an undesirable immune reaction to a treatment with a vaccine or a gene therapy composition.

WO 2022/063892 A1